A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis

BACKGROUND: Patients with idiopathic pulmonary fibrosis (IPF) often do not tolerate pirfenidone in the recommended dose of 2400 mg/day. The proportion of patients requiring dose reduction and its impact on survival in the real-world remain unclear. METHODS: Consecutive subjects with IPF were enrolle...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sarcoidosis Vasc Diffuse Lung Dis
Autors principals: Dhooria, Sahajal, Agarwal, Ritesh, Sehgal, Inderpaul Singh, Prasad, Kuruswamy Thurai, Muth, Valliappan, Garg, Mandeep, Bal, Amanjit, Aggarwal, Ashutosh Nath, Behera, Digambar
Format: Artigo
Idioma:Inglês
Publicat: Mattioli 1885 2020
Matèries:
Original Article: Clinical Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7569556/
https://ncbi.nlm.nih.gov/pubmed/33093778
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.36141/svdld.v37i2.8718
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars